


## **Executive Interview - Shield Therapeutics**



Watch video >

Shield Therapeutics is a UK-based, speciality pharmaceutical company with a primary focus on commercialising its drug Feraccru, which is approved in Europe for the treatment of iron deficiency, with or without anaemia. In this video, healthcare analyst Dr Sean Conroy provides an overview of Shield Therapeutics and outlines the company's strategy for the commercialisation of Feraccru. He finishes the video by detailing Edison's approach to valuing the company.

See latest research note here.



Dr Sean Conroy Healthcare analyst Email: healthcare@edisongroup.com Tel: +44 (0) 20 3077 5700

Registered in England, no. 4794244. Registered Office: 280 High Holborn, London, WC1V 7EE UK.
Copyright 2018 all rights reserved Edison Investment Research Limited.
Authorised and Regulated by the Financial Conduct Authority.

<u>Click here</u> for the authorisations and regulations that apply to Edison